- Home
- LEN vs VTRS Comparison
LEN vs VTRS Comparison
Compare LEN & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEN | VTRS |
|---|---|---|
| Founded | 1954 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1B | 21.0B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LEN | VTRS |
|---|---|---|
| Price | $84.81 | $18.05 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 21 | 12 |
| Target Price | ★ $77.87 | $19.70 |
| AVG Volume (30 Days) | 4.9M | ★ 8.5M |
| Earning Date | 09-16-2026 | 11-05-2026 |
| Dividend Yield | 2.37% | ★ 2.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.36 | 0.05 |
| Revenue | ★ $34,186,934,000.00 | $14,299,900,000.00 |
| Revenue This Year | N/A | $3.44 |
| Revenue Next Year | $2.98 | $1.68 |
| P/E Ratio | ★ $25.12 | $370.63 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $71.78 | $9.92 |
| 52 Week High | $133.76 | $18.75 |
Technical Indicators
Market Signals| Indicator | LEN | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.81 | 55.16 |
| Support Level | $82.48 | $15.94 |
| Resistance Level | $89.39 | $18.30 |
| Average True Range (ATR) | 2.70 | 0.47 |
| MACD | 1.06 | 0.03 |
| Stochastic Oscillator | 100.00 | 64.78 |
Price Performance
Historical ComparisonAbout LEN Lennar Corporation
Lennar is the second-largest public homebuilder in the United States, behind D.R. Horton, operating in 26 states. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.